Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.53 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.53 |
| ▸ | DDX3X | O00571 | 2/20 | 0.53 |
| ▸ | BLK | P51451 | 1/20 | 0.51 |
| ▸ | F2R | P25116 | 2/20 | 0.50 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | FADS1 | O60427 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL811056 | 0.87 | KCNK3 (0.68) | SMN1; SMN2ALDH1A1PTGS1KCNK3KCNK9 | |
| SCHEMBL8402949 | 0.81 | ALDH1A1 (0.79) | SMN1; SMN2ALDH1A1PTGS1KCNK3KCNK9 | |
| SCHEMBL28973539 | 0.81 | JAK2 (0.67) | SMN1; SMN2ALDH1A1PTGS1KCNK3KCNK9 | |
| SCHEMBL16430921 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1DDX3XMAPTMEN1 | |
| SCHEMBL11573735 | 0.78 | MEN1 (0.65) | SMN1; SMN2ALDH1A1MAPTFADS1MEN1 | |
| SCHEMBL16441856 | 0.78 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1PTGS1DDX3XFADS1 | |
| SCHEMBL9810110 | 0.77 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1PTGS1DDX3XBLK | |
| SCHEMBL16430819 | 0.76 | NPC1 (0.62) | SMN1; SMN2ALDH1A1PTGS1KCNK3DDX3X | |
| SCHEMBL11305806 | 0.76 | FADS1 (0.58) | SMN1; SMN2ALDH1A1PTGS1PTGS2MAPT | |
| SCHEMBL19442228 | 0.76 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1KCNK3KCNK9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168132-A1 | DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | MINORYX THERAPEUTICS S.L. (ES) | 2016-06-16 | — | — | US | disclosed |
| US-20160168132-A1 | DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | MINORYX THERAPEUTICS S.L. (ES) | 2016-06-16 | — | — | US | disclosed |
| US-20160168132-A1 | DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | MINORYX THERAPEUTICS S.L. (ES) | 2016-06-16 | — | — | US | disclosed |
| EP-3027590-A1 | DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Minoryx Therapeutics S.L. (ES) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015014900-A1 | DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | MINORYX THERAPEUTICS S.L. (ES) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015014900-A1 | DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | MINORYX THERAPEUTICS S.L. (ES) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168132-A1 | DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | GLB1, GBA1, GALC | SMN1; SMN2 286/4885ALDH1A1 374/4885PTGS1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.